Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data
Helen-Cara Younan, Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Joanne Evans, Spyridon Gennatas(Guy's and St Thomas' NHS Foundation Trust), Waleed Mohammed, Eleni Karapanagiotou(King's College London), James Spicer(King's College London), Sopozme Toghey, Alex Giorgiou, Olivia Hatcher, Shaymaa Altharwane, Amish Lakhani, Zartaj Ahmed, Max Julve, Manar Almusarhed, Riyaz Shah(Maidstone and Tunbridge Wells NHS Trust), Shuai Zhang, Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Debashree Roy, Amit Samani, Elias Pintus(Guy's and St Thomas' NHS Foundation Trust), Danielle Power, María Luisa Lazo de la Vega Monroy, Sharmistha Ghosh(Guy's and St Thomas' NHS Foundation Trust), Stephanie Slater(University Hospital Crosshouse), Samreen Ahmed(University Hospitals of Leicester NHS Trust), Tom Newsom‐Davis
Cited by 0
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|614